MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
Open Access
- 25 October 2021
- journal article
- research article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2021, 1-13
Abstract
Objective. This study is aimed at exploring the underlying molecular mechanisms of ST-segment elevation myocardial infarction (STEMI) and provides potential clinical prognostic biomarkers for STEMI. Methods. The GSE60993 dataset was downloaded from the GEO database, and the differentially expressed genes (DEGs) between STEMI and control groups were screened. Enrichment analysis of the DEGs was subsequently performed using the DAVID database. A protein–protein interaction network was constructed, and hub genes were identified. The hub genes in patients were then validated by quantitative reverse transcription-PCR. Furthermore, hub gene-miRNA interactions were evaluated using the miRTarBase database. Finally, patient data on classical cardiovascular risk factors were collected, and plasma microRNA-146a (miR-146a) levels were detected. An individualized nomogram was constructed based on multivariate Cox regression analysis. Results. A total of 239 DEGs were identified between the STEMI and control groups. Expression of S100A12 and miR-146a was significantly upregulated in STEMI samples compared with controls. STEMI patients with high levels of miR-146a had a higher risk of major adverse cardiovascular events (MACEs) than those with low levels of miR-146a (log-rank ). Multivariate Cox regression analysis identified five statistically significant variables, including age, hypertension, diabetes mellitus, white blood cells, and miR-146a. A nomogram was constructed to estimate the likelihood of a MACE at one, two, and three years after STEMI. Conclusion. The incidence of MACEs in STEMI patients expressing high levels of miR-146a was significantly greater than in those expressing low levels. MicroRNA-146a can serve as a biomarker for adverse prognosis of STEMI and might function in its pathogenesis by targeting S100A12, which may exert its role via an inflammatory response. In addition, our study presents a valid and practical model to assess the probability of MACEs within three years of STEMI.Keywords
Funding Information
- Xuzhou Municipal Science and Technology Bureau (KC20097)
This publication has 45 references indexed in Scilit:
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- DAVID-WS: a stateful web service to facilitate gene/protein list analysisBioinformatics, 2012
- The altered expression of inflammation-related microRNAs with microRNA-155 expression correlates with Th17 differentiation in patients with acute coronary syndromeCellular & Molecular Immunology, 2011
- Utility of Absolute and Relative Changes in Cardiac Troponin Concentrations in the Early Diagnosis of Acute Myocardial InfarctionCirculation, 2011
- MicroRNAs expression in ox-LDL treated HUVECs: MiR-365 modulates apoptosis and Bcl-2 expressionBiochemical and Biophysical Research Communications, 2011
- S100A12 in Vascular Smooth Muscle Accelerates Vascular Calcification in Apolipoprotein E–Null Mice by Activating an Osteogenic Gene Regulatory ProgramArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 ResponsesCell, 2010
- microRNA-222 Controls Neovascularization by Regulating Signal Transducer and Activator of Transcription 5A ExpressionArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophagesCardiovascular Research, 2009
- Apoptosis and Post-infarction Left Ventricular RemodelingJournal of Molecular and Cellular Cardiology, 2002